Jiangsu Alphamab Biopharmaceuticals Co., Ltd

This study tests a new drug called JSKN016 combined with chemotherapy or immunotherapy for people with HER2-negative breast cancer that cannot be surgically removed or has spread. About 180 adults aged 18-75 will join. The goal is to see if the combination shrinks tumors and is s…

This early-stage trial tests whether JSKN022 is safe for people with advanced solid tumors that have not responded to standard treatments. About 225 adults will receive the drug to check for side effects and see if it can shrink tumors. The main goal is to find a safe dose and un…

This study tests a new drug called JSKN016 against standard treatments chosen by the doctor for people with advanced triple-negative breast cancer that has worsened after at least two prior therapies. About 364 adults aged 18 to 75 will take part. The goal is to see if JSKN016 he…

This study tests a new drug called JSKN003 against standard chemotherapy in about 400 people with HER2-low breast cancer that has spread or come back. Participants are randomly assigned to receive either JSKN003 or a standard chemo drug chosen by their doctor. The main goal is to…